They only need one to rocket the stock but I believe they are going to hit at least two and very likely all three. Plus they are accelerating a very exciting new class of cancer drug NCE001. And don't forget about the ORP diagnostic. The 5,000 patient trial is finished and I believe they are getting ready to announce something major.
Sentiment: Strong Buy